Kiyotaka Yoh

Suggest Changes
Learn More
BACKGROUND Optimum management strategies for patients with advanced non-small-cell lung cancer (NSCLC) with acquired resistance to EGFR tyrosine-kinase inhibitors are undefined. We aimed to assess(More)